Stanford Research | VETS

Veterans Experience Major PTSD and Depression Relief From Psychedelic Drug Ibogaine

This news report examines Stanford Medicine’s one-year follow-up study of Special Operations veterans who received ibogaine treatment, supported in part by VETS, and how the findings add to the growing body of research and federal attention on psychedelic-assisted therapy for veterans.

One year after taking ibogaine, veterans find continued relief from PTSD

A new Stanford Medicine study published in Translational Psychiatry follows Special Operations veterans for one year after ibogaine treatment, funded by VETS at a vetted, third-party facility, offering the most extensive look to date at the long-term potential of this therapy for PTSD, depression, and anxiety.

1.30.2026
Stanford Research

Men’s Journal: Study — New Psychedelic Drug Combo Improves PTSD

Reports on the mystical-experience paper, noting PTSD symptom reductions in 30 male veterans after magnesium–ibogaine treatment. It presents the findings as preliminary support for larger PTSD trials.

8.1.2025
Stanford Research

Neurology Advisor: Magnesium–Ibogaine May Be Beneficial for Combat Veterans With TBI

Reports that magnesium–ibogaine may benefit combat veterans with TBI based on observed resting-state brain-wave changes. The piece focuses on altered cortical oscillations and links those signals to psychiatric and cognitive outcomes.

7.24.2025
Stanford Research

News-Medical: Ibogaine treatment shows major breakthrough for veterans with brain injuries

Covers the Nature Mental Health paper on magnesium–ibogaine effects on cortical oscillations and neural complexity. It highlights the study as evidence that ibogaine may produce measurable brain-function changes in veterans with TBI.

1
2
3
7